SOM 230 and Everolimus in Combination for the Treatment of Prostate Cancer

Share this content:
SOM 230 and Everolimus in Combination for the Treatment of Prostate Cancer
 
Sponsors and Collaborators
Thomas Jefferson University
Novartis Pharmaceuticals
 
Contact
Jianqing Lin, MD
215-955-8874
 
Clinical Research Management Office
215-955-1661
 
Investigator
Jianqing Lin, MD
Thomas Jefferson University
 
ClinicalTrials.gov Identifier

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs